Zydus Lifesciences Ltd reported consolidated revenue from operations of Rs 61.23 billion for the September 2025 quarter, driven by robust growth in India and the US markets. The company also saw healthy gains in operating profit and net income, supported by product launches and cost discipline.
Zydus Lifesciences Ltd has announced its financial results for the second quarter of FY2025–26, showcasing a solid performance across key geographies. The company posted consolidated revenue of Rs 61.23 billion for the quarter ended September 30, 2025, reflecting an 8.4% year-on-year growth.
The pharmaceutical major benefited from strong demand in India and the US, with new product launches and strategic portfolio expansion contributing to topline momentum. Operating profit rose 3.06% to Rs 1.98 billion, while EBITDA increased 7.58% to Rs 2.13 billion. Net profit for the quarter stood at Rs 1.52 billion, marking a 38% jump from the previous year.
Zydus also reported a significant rise in other income and maintained healthy margins despite currency fluctuations and regulatory headwinds. The company continues to invest in R&D and is exploring fundraising options to support future growth.
Major Takeaways
- Q2 FY2025–26 consolidated revenue: Rs 61.23 billion
- Net profit: Rs 1.52 billion, up 38% year-on-year
- EBITDA: Rs 2.13 billion, up 7.58%
- Strong sales in India and US markets
- Continued investment in R&D and portfolio expansion
Sources: Economic Times, ScanX News, Zydus Lifesciences Investor Presentation, Business Standard